Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 17/20 | 0.72 |
| ▸ | MMP9 | P14780 | 17/20 | 0.72 |
| ▸ | MMP3 | P08254 | 4/20 | 0.52 |
| ▸ | MMP13 | P45452 | 4/20 | 0.52 |
| ▸ | MMP8 | P22894 | 2/20 | 0.45 |
| ▸ | MMP14 | P50281 | 2/20 | 0.45 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4700891 | 1.00 | MMP2 (0.72) | MMP2MMP9MMP3MMP13MMP8 | |
| SCHEMBL3109584 | 0.93 | MMP2 (0.74) | MMP2MMP9MMP3MMP13MMP8 | |
| SCHEMBL3109580 | 0.93 | MMP2 (0.74) | MMP2MMP9MMP3MMP13MMP8 | |
| SCHEMBL14040504 | 0.90 | MMP2 (0.57) | MMP2MMP9MMP3MMP13F10 | |
| SCHEMBL4703218 | 0.90 | MMP2 (0.57) | MMP2MMP9MMP3MMP13F10 | |
| SCHEMBL4698688 | 0.87 | MMP2 (0.68) | MMP2MMP9MMP3MMP13MMP8 | |
| SCHEMBL4698686 | 0.87 | MMP2 (0.68) | MMP2MMP9MMP3MMP13MMP8 | |
| SCHEMBL4702649 | 0.85 | MMP2 (0.58) | MMP2MMP9MMP3MMP13 | |
| SCHEMBL4702643 | 0.85 | MMP2 (0.58) | MMP2MMP9MMP3MMP13 | |
| SCHEMBL8203481 | 0.84 | MMP2 (1.00) | MMP2MMP9MMP3MMP13MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009001021-A1 | IMIDAZOPYRIDINE DERIVATIVES USEFUL AS ENZYME INHIBITORS FOR THE TREATMENT OF CELL PROLIFERATIVE AND AUTOIMMUNE DISEASES | CHROMA THERAPEUTICS LTD. (GB) | 2008-12-31 | — | — | WO | disclosed |
| EP-1444202-B1 | NOVEL METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-10-15 | — | — | EP | disclosed |
| US-7132434-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2006-11-07 | — | — | US | disclosed |
| US-20050026990-A1 | Novel metalloproteinase ihibitors | ASTRAZENECA AB (SE) | 2005-02-03 | — | — | US | disclosed |
| EP-1444202-A1 | NOVEL METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003040098-A1 | NOVEL METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026990-A1 | Novel metalloproteinase ihibitors | MMP12, MMP1, MMP16 | MMP2 12/4885MMP9 14/4885MMP3 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.